Virica Biotech news
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, will be featured in a live webinar to be held on Monday, November 14, 2022, at 2:30pm EST. This webinar will focus on
Virica Biotech Inc. (“Virica”), a leading developer of solutions for scaling of viral medicines, today announced it has received $400,000 from Innovation, Science and Economic Development Canada (ISED) through the Innovative Solutions Canada (ISC) program. This funding supports Virica’s collaboration with the National Research Council of Canada’s (NRC) Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable version of AAV-LPL, a gene thera
Virica Biotech Inc., a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford BioMedica plc (LSE:OXB), a leading gene and cell therapy company, to improve the yield and production efficiency of Oxford Biomedica’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers
Virica is excited to be a part of Advanced Therapies Week, Jan 25th-Jan28th, 2022 at the Miami Convention Center. We are a proud to be a Dynamk Capital portfolio company. Visit us in the Technology of Tomorrow Zone, Booth 11.
We look forward to meeting you at Advance Therapies Week!
We now have officially launched our Process Innovation Facility! Take a look at where we enhance the manufacturing of viral medicine.